消癌平注射液联合表柔比星新辅助化疗治疗三阴性乳腺癌的临床疗效

Clinical Efficacy of Xiao'aiping Injection Combined with Epirubicin Neoadjuvant Chemotherapy for Triple Negative Breast Cancer

目的探讨消癌平注射液联合表柔比星新辅助化疗治疗三阴性乳腺癌患者的临床疗效。方法选取本院收治的三阴性乳腺癌患者80例,按照随机数字表法平均分为两组,对照组患者接受表柔比星新辅助化疗,观察组患者在对照组基础上应用消癌平注射液。对比两组患者的临床疗效、治疗前后IL-6、IL-8、TNF-α水平、生活质量以及不良反应。结果观察组患者临床疗效明显优于对照组(P<0.05);治疗前两组患者IL-6、IL-8、TNF-α水平无显著差异(P>0.05),治疗后观察组明显优于对照组(P<0.05);治疗前两组患者躯体、角色、认知、情绪以及社会功能评分无明显差异(P>0.05),治疗后观察组上述评分均显著高于对照组(P<0.05);观察组患者不良反应发生率明显低于对照组(P<0.05)。结论消癌平注射液联合表柔比星新辅助化疗治疗三阴性乳腺癌的效果显著,值得临床推广应用。

Objective To explore the clinical efficacy of Xiao'aiping injection combined with neo-adjuvant chemotherapy with epirubicin in the treatment of triple negative breast cancer.Methods Eighty patients diagnosed with triple-negative breast cancer in our hospital were selected and divided into two groups by random number table.The patients in the control group were treated with epirubicin alone.And those in observation group were treated with Xiao'aiping injection and epirubicin.The clinical efficacy,levels of IL-6,IL-8,TNF-α,quality of life,and adverse reactions before and after treatment were compared between the two groups.Results The clinical efficacy of the observation group was significantly better than that of the control group(P<0.05).There was no significant difference in the levels of IL-6,IL-8 and TNF-αbefore treatment between the two groups(P>0.05).After treatment,the levels of IL-6 and IL-8 were significantly lower in observation group than in control group(P<0.05),while the TNF-αlevel was higher in observation group than in control group(P<0.05).Before treatment,there were no significant differences in the scores of body,role,cognition,emotion and social function between the two groups(P>0.05).However,after treatment,the scores of the above mentioned were significantly higher in observation group than in control group(P<0.05).The adverse reactions in the observation group were significantly less than in the control group(P<0.05).Conclusion Xiao'aiping injection combined with epirubicin neoadjuvant chemotherapy is effective for triple negative breast cancer pateints.It is worthy of extensive clinical application.